Hoth Therapeutics Reports It Selected NUVISAN For Manufacturing Of Its HT-001 Drug Batches For The CLEER Study
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in